Neoplastic Progression
Neoplastic Progression - Related Videos
05:15
Grossing of Non-neoplastic Globes, Including Fetal Eyes
0 Views •
Cited by 1 •
2025
Thorough grossing and standardized sectioning of non-neoplastic globes are important for obtaining high-quality reproducible histopathologic sections. Guidelines for a standardized grossing of adult and fetal non-neoplastic globes are provided herein. Different options for globe sectioning are demonstrated and discussed, including criteria for case-based decision-making.
09:05
Generation and Quantitative Analysis of Pulsed Low Frequency Ultrasound to Determine the Sonic Sensitivity of Untreated and Treated Neoplastic Cells
0 Views •
2015
Selective damage of human leukemia cells can be achieved through a novel approach of applying low frequency ultrasound both with and without chemotherapeutic pretreatment of leukemic and normal hematopoietic cells.
02:07
Tumor Progression
0 Views •
2023
Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages. Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
02:07
Tumor Progression
0 Views •
2021
Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages. Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
12:42
Heterotypic Three-dimensional In Vitro Modeling of Stromal-Epithelial Interactions During Ovarian Cancer Initiation and Progression
0 Views •
Cited by 19 •
2012
We describe methodologies for establishing in vitro heterotypic three-dimensional models comprising ovarian fibroblasts and normal ovarian surface or ovarian cancer epithelial cells. We discuss the use of these models to study stromal-epithelial interactions that occur during ovarian cancer development.
FAQs
Clonal selection changes the composition of a tumor over time. Genetic or epigenetic alterations can give one cell population an advantage, allowing it to expand relative to others. Successive populations may therefore accumulate traits linked to proliferation, survival, invasion, or metastasis, creating biologically different tumor subgroups.
The tumor microenvironment influences which tumor traits become consequential during progression. Its interaction with abnormal cell populations is considered alongside genetic and epigenetic change, particularly when studying angiogenesis, tissue invasion, and metastatic capacity. Including this context helps explain why tumor behavior reflects both cellular alterations and the surrounding biological setting.
A localized growth remains confined, whereas progression toward invasive or metastatic cancer reflects acquisition of additional capabilities. Uncontrolled proliferation expands tumor burden; resistance to cell death can preserve abnormal cells; angiogenesis becomes part of the evolving tumor behavior; and tissue invasion or metastatic capacity indicates spread beyond the original site.
Genetic and epigenetic alterations provide distinct but connected routes for changing tumor-cell behavior. Their accumulation can contribute to uncontrolled proliferation, resistance to cell death, angiogenesis, invasion, and metastasis. For medicine, tracking these changes helps relate tumor biology to classification, prognosis, molecular biomarkers, and the selection of targeted therapies.
Medical evaluation of neoplastic progression connects observed tumor behavior with molecular information. Classification and prognostic assessment can be interpreted alongside molecular biomarkers that reflect relevant alterations or tumor characteristics. This approach does not treat a tumor as biologically static; it supports decisions about targeted therapies and helps recognize features associated with progression or resistance.
Molecular biomarkers are useful because they translate features of evolving tumor populations into information that can support clinical interpretation. In the context of neoplastic progression, they may contribute to tumor classification, prognosis, and decisions about targeted therapy. Their value is greatest when considered with the tumor’s changing biology rather than as an isolated label.
Studying neoplastic progression supports more than treatment selection. It can guide cancer prevention and early-detection strategies by clarifying the changes associated with worsening tumor behavior. It also focuses research on limiting treatment resistance, a problem linked to evolving cell populations. These aims connect mechanistic cancer biology with practical medical goals across the disease course.